Sequoia Capital China has led over $100 million Series B funding round in industrial synthetic biotech firm Bota Biosciences with the participation of new investor CMB International Capital, a Hong Kong-based subsidiary of China Merchants Bank.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
